Comparison of intravitreal anti-VEGF agents and oral carbonic anhydrase inhibitors in the treatment of cystoid macular edema secondary to retinitis pigmentosa
Both intravitreal anti-VEGF agents and oral CAIs effectively improved CMT and BCVA in RP-CME patients within the first 3 months of treatment. However, oral CAIs demonstrated superior anatomic and functional improvements at 6 months. Poorer BCVA prognosis was associated with older age, higher baseline CMT, poorer baseline visual acuity. Larger, randomized clinical trials with extended follow-up periods are needed to confirm these findings.
Authors
- Y.H. Diao
- Yuke Ji
- Lujia Feng (ORCID: https://orcid.org/0000-0002-5046-7544)
- Lu Chen (ORCID: https://orcid.org/0000-0003-0765-6662)
- Xueping Wu (ORCID: https://orcid.org/0000-0002-9563-3796)
- Liang Jia (ORCID: https://orcid.org/0009-0001-7752-8538)
- Huiyan Zheng
- Zhenhua Zou (ORCID: https://orcid.org/0000-0003-0296-6231)
- Shaochong Zhang (ORCID: https://orcid.org/0000-0002-2212-7139)
- Dong Fang
- Xiangqing Hei
Institutions
- Xiamen University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-12-10
- DOI
- https://doi.org/10.3389/fphar.2024.1477889
- Citations
- 2
- Primary Topic
- Retinal Development and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.47